Follicular Lymphoma (FL) is a slow-growing type of non-Hodgkin lymphoma that arises from B-lymphocytes. It typically presents with painless, swollen lymph nodes and may progress over time to a more aggressive form. While not usually curable, it is treatable with therapies such as monoclonal antibodies, chemotherapy, and targeted agents, often offering long remission periods.
<h3 dir="ltr">Epidemiology Segmentation</h3>
<ul>
<li dir="ltr" aria-level="1">
Total Diagnosed Incidence Cases of Follicular Lymphoma
</li>
<li dir="ltr" aria-level="1">
Gender-specific Cases of Follicular Lymphoma
</li>
<li dir="ltr" aria-level="1">
Age-specific cases of Follicular Lymphoma
</li>
<li dir="ltr" aria-level="1">
Stage-Specific Cases of Follicular Lymphoma
</li>
<li dir="ltr" aria-level="1">
Grade-Specific Cases of Follicular Lymphoma
</li>
<li dir="ltr" aria-level="1">
Treated Case by Line of therapy of Follicular lymphoma
</li>
</ul>
<h2 dir="ltr"><a href="https://www.delveinsight.com/report-store/follicular-lymphoma-epidemiology-forecast">Follicular Lymphoma Epidemiology</a></h2>
<ul>
<li dir="ltr" aria-level="1">
In 2024, approximately 35K diagnosed cases of follicular lymphoma were reported across the 7MM.
</li>
<li dir="ltr" aria-level="1">
The US accounted for the highest share, with about 17K cases, expected to rise by 2034.
</li>
<li dir="ltr" aria-level="1">
Most cases occurred in the 60&ndash;80 age group (~9K), followed by the 40&ndash;59 group (~4K).
</li>
<li dir="ltr" aria-level="1">
Stage IV cases accounted for approximately 35% of the total diagnosed population in 2024.
</li>
</ul>
<h2 dir="ltr"><a href="https://www.delveinsight.com/report-store/follicular-lymphoma-market-insights">Follicular Lymphoma Market</a></h2>
<ul>
<li dir="ltr" aria-level="1">
In 2024, the follicular lymphoma market size in the 7MM was around USD 1.6 billion.
</li>
<li dir="ltr" aria-level="1">
The US led the market, contributing approximately USD 1 billion.
</li>
<li dir="ltr" aria-level="1">
In the EU4 and the UK, Germany had the highest market share at about USD 100 million.
</li>
</ul>
<h3 dir="ltr">Follicular Lymphoma Market Drivers</h3>
<ul>
<li dir="ltr" aria-level="1">
Increasing adoption of monoclonal antibodies, CAR-T cell therapies, and bispecific antibodies is driving treatment innovation.
</li>
<li dir="ltr" aria-level="1">
Enhanced awareness among healthcare providers and patients promotes earlier detection and treatment initiation.
</li>
<li dir="ltr" aria-level="1">
Robust clinical pipeline with multiple agents in late-stage development fuels market growth.
</li>
</ul>
<h3 dir="ltr">Follicular Lymphoma Market Barriers</h3>
<ul>
<li dir="ltr" aria-level="1">
CAR-T and novel biologics come with significant price tags, limiting accessibility.
</li>
<li dir="ltr" aria-level="1">
Despite initial response, many patients relapse or develop resistance to current treatments.
</li>
<li dir="ltr" aria-level="1">
Older patients may not tolerate aggressive therapies, narrowing their treatment choices.
</li>
</ul>
<h3 dir="ltr"><a href="https://www.delveinsight.com/report-store/follicular-lymphoma-pipeline-insight">Follicular Lymphoma Key Therapies</a></h3>
<ul>
<li dir="ltr" aria-level="1">
Zilovertamab Vedotin
</li>
<li dir="ltr" aria-level="1">
CALQUENCE (Acalabrutinib)
</li>
<li dir="ltr" aria-level="1">
CTX112
</li>
<li dir="ltr" aria-level="1">
BGB-16673
</li>
<li dir="ltr" aria-level="1">
NKTR-255
</li>
<li dir="ltr" aria-level="1">
NVG-111
</li>
<li dir="ltr" aria-level="1">
AS-1763 (docirbrutinib)
</li>
<li dir="ltr" aria-level="1">
Cemacabtagene Ansegedleucel (ALLO-501)
</li>
<li dir="ltr" aria-level="1">
Abexinostat
</li>
<li dir="ltr" aria-level="1">
Golcadomide
</li>
<li dir="ltr" aria-level="1">
MONJUVI (tafasitamab)
</li>
<li dir="ltr" aria-level="1">
AZD0486
</li>
</ul>
<h3 dir="ltr">Follicular Lymphoma Key Players</h3>
<ul>
<li dir="ltr" aria-level="1">
Merck Sharp and Dohme
</li>
<li dir="ltr" aria-level="1">
AstraZeneca
</li>
<li dir="ltr" aria-level="1">
CRISPR Therapeutics
</li>
<li dir="ltr" aria-level="1">
BeiGene
</li>
<li dir="ltr" aria-level="1">
Nektar Therapeutics
</li>
<li dir="ltr" aria-level="1">
NovalGen
</li>
<li dir="ltr" aria-level="1">
Carna Biosciences
</li>
<li dir="ltr" aria-level="1">
Allogene Therapeutics
</li>
<li dir="ltr" aria-level="1">
Xynomic Pharmaceuticals
</li>
<li dir="ltr" aria-level="1">
Bristol-Myers Squibb
</li>
<li dir="ltr" aria-level="1">
Incyte Corporation
</li>
</ul>
And others.

Follicular Lymphoma Market Infographics

Follicular Lymphoma Symptoms, Treatment, epidemiology, companies, drugs, infographic is a short guide to understand the problem and market landscape